The Global attention deficit hyperactivity disorder drug market is expected to grow at a significant CAGR during the forecast period. ADHD is one of the most prevalent pediatric neurodevelopmental diseases. It is most commonly diagnosed in childhood and adult. Children with attention deficit hyperactivity disorder may have trouble paying attention, regulating impulsive behaviours (doing things without considering the consequences), or being overly active. Attention deficit hyperactivity disorder has differences in brain development and brain activity that affect attention, the ability to sit still, and self-control.. Attention deficit hyperactivity disorder is a neurological disorder. It is one of the most prevalent psychological disorders that affects both children and adults. According to the American Psychiatric Association, in 2018, 2.5 % and 5% of children in the United States  had attention deficit hyperactivity disorder. The disorder is more frequent in boys than in girls among children. A person with attention deficit hyperactivity disorder (ADHD) has difficulty sitting still, focusing on tasks, and paying attention. This condition can be identified in children aged 6 to 12 who do not consider before acting. The market for attention deficit hyperactivity disorder is being driven by an increase in the number of pre-term deliveries of newborns. According to the University of Maryland Medical Center (UMMC), this disease affects 20% of prematurely born babies currently. Pregnant women's increased intake of toxins such as alcohol, cigarettes, and drugs results in children with attention deficit hyperactivity disorder (ADHD). Governments all around the world are paying attention to the growing number of people suffering from a number of psychological disorders, including attention deficit hyperactivity disorder (ADHD). The New South Wales is a southeastern Australian state. The state  government is investing $7.7 million in regional NSW to test a new approach of care and management for children with behavioural difficulties, such as attention deficit hyperactivity disorder (ADHD).

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

• Competitive Landscape- Pfizer Inc., Eli Lilly and Company., Novartis AG., GlaxoSmithKline PLC., Mallinckrodt Pharmaceuticals., Hisamitsu Pharmaceutical Co., Inc., and Johnson & Johnson., among others.  

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Attention Deficit Hyperactivity Disorder Drug Market Market Segmentation

By Type

    • Stimulants

    • Amphetamine

    • Methylphenidate

    • Dextroamphetamine

    • Dexmethylphenidate

    • Lisdexamfetamine dimesylate

    • Non-stimulants

    • Atomoxetine

    • Bupropion

    • Guanfacine

    • Clonidine

By Application

    • Hospital Pharmacies

    • Speciality Clinics

    • Retail Pharmacies

    • e-Commerce

By Age group

    • Pediatric and Adolescent

    • Adults

Global Attention deficit hyperactivity disorder drug market by Region

North America

    • United States 

    • Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• Japan

• India

• Rest of Asia-Pacific 

Rest of World

    • Latin America 

    • The Middle East and Africa